---
title: "LeonaBio | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285657437.md"
datetime: "2026-05-08T03:21:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285657437.md)
  - [en](https://longbridge.com/en/news/285657437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285657437.md)
generator: "portal-rs"
---

# LeonaBio | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -1.73, beating the estimate of USD -2.5.

EBIT: As of FY2026 Q1, the actual value is USD -17.8 M.

#### Financial Position

-   Cash, cash equivalents, and investments were $67.7 million as of March 31, 2026, compared to $88.3 million as of December 31, 2025.
-   Total assets were $71.590 million as of March 31, 2026, down from $92.151 million as of December 31, 2025.
-   Total liabilities were $22.287 million as of March 31, 2026, compared to $64.361 million as of December 31, 2025.
-   Stockholders’ equity increased to $49.303 million as of March 31, 2026, from $27.790 million as of December 31, 2025.
-   The Sermonix pre-funded warrant liability was $0 as of March 31, 2026, down from $37.488 million as of December 31, 2025.
-   Milestone liability was $14.187 million as of March 31, 2026, compared to $15.116 million as of December 31, 2025.

#### Operating Results

-   Net cash used in operations was $20.9 million for the quarter ended March 31, 2026, an increase from $14.7 million for the same period in 2025.
-   Research and Development (R&D) expenses were $11.262 million for the quarter ended March 31, 2026, significantly up from $4.302 million for the quarter ended March 31, 2025, primarily due to clinical trial spend related to the ELAINE-3 trial for lasofoxifene.
-   General and Administrative (G&A) expenses were $6.881 million for the quarter ended March 31, 2026, compared to $5.234 million for the quarter ended March 31, 2025, primarily due to professional service fees.
-   The net loss for the quarter ended March 31, 2026, was - $32.948 million, compared to a net loss of - $9.143 million for the same period in 2025.
-   Net loss per share attributable to common stockholders was - $1.73 for the quarter ended March 31, 2026, compared to - $2.34 per share for the quarter ended March 31, 2025.
-   Milestone liability change in fair value resulted in a - $0.929 million impact for the quarter ended March 31, 2026.
-   Other income, net, was $0.586 million for the quarter ended March 31, 2026, up from $0.393 million for the same period in 2025.
-   Sermonix pre-funded warrant change in fair value resulted in a - $16.320 million impact for the quarter ended March 31, 2026.

#### Operational Metrics and Business Updates

-   LeonaBio is advancing lasofoxifene in a Phase 3 clinical trial (ELAINE-3) for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, with the trial protocol being amended to increase the sample size from 500 to up to 600 participants.
-   ATH-1105, a small molecule drug candidate for neurodegenerative diseases, demonstrated a favorable safety and tolerability profile, dose-proportional pharmacokinetics, and CNS penetration in its first-in-human Phase 1 clinical trial, with preclinical evidence supporting its potential for ALS treatment.
-   LeonaBio appointed Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective May 5, 2026, while John Fluke, Jr. retired from the Board effective May 4, 2026.
-   The company hosted a virtual Key Opinion Leader event to discuss the evolving treatment landscape in metastatic breast cancer and the potential of lasofoxifene.

#### Outlook / Guidance

LeonaBio expects to complete enrollment of the Phase 3 ELAINE-3 clinical trial in the fourth quarter of 2026, with topline data anticipated in the second half of 2027. The company is also on track to initiate a Phase 2 proof-of-concept study of ATH-1105 in ALS patients in the second half of 2026. With a strengthened balance sheet from recent financing, LeonaBio believes it is well-positioned to achieve multiple value-creating milestones in 2026 and beyond.

### Related Stocks

- [LONA.US](https://longbridge.com/en/quote/LONA.US.md)

## Related News & Research

- [Athira Pharma (NASDAQ:LONA) Announces Quarterly Earnings Results](https://longbridge.com/en/news/295983245.md)
- [LeonaBio Q2 net loss widens on higher R&D spending](https://longbridge.com/en/news/295971106.md)
- [LeonaBio targets Phase 3 ELAINE-3 enrollment completion in Q4 2026, topline data seen in H2 2027](https://longbridge.com/en/news/295655741.md)
- [LeonaBio spotlights lasofoxifene at DAVA Oncology breast cancer summit](https://longbridge.com/en/news/295654419.md)
- [Queen’s Road Capital publishes MD&A for nine months ended May 31, 2026](https://longbridge.com/en/news/292480941.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**